Rockville-based biodefense company Emergent BioSolutions, taking steps to move deeper into the commercial drugmaking world, is paying $222 million to buy Cangene Corp., a Canadian firm, according to the Washington Post.
Emergent emerged as a key biodefense company following the Sept. 11 attacks, when it sold Anthrax vaccines to the U.S. government.